SMW Free Realtime Trade Alerts -- Fast Moving Stocks < $15 -- Join Today for FREE!!
Alimera Sciences, Inc.(NASDAQ : ALIM)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Loading ALIM News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||1.45%||74.40||1.0%||$719.30m|
|SRPT||Sarepta Therapeutics, Inc.||2.64%||49.08||21.0%||$256.94m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.65%||370.77||3.6%||$251.10m|
|ALXN||Alexion Pharmaceuticals, Inc.||1.38%||121.97||2.5%||$158.67m|
|CLVS||Clovis Oncology, Inc.||5.92%||34.53||32.9%||$157.87m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.91%||82.58||2.7%||$130.61m|
|BMRN||BioMarin Pharmaceutical Inc.||-1.27%||84.32||4.4%||$92.43m|
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. It focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by C. Daniel Myers and David R. Holland and is headquartered in Alpharetta, GA.